Currently early-phase and phase I clinical trials have proved higher response rate for the cancer patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors than for those without the mutations [23]–[25]. This evidence concerns the gene PIK3CA and cancer.